An Iowa lawmaker who had pushed for the passage Gov. Kim Reynolds’ decision to veto a bill pertaining to the psychoactive ...

Findings showed COMP360 psilocybin statistically significantly reduced symptom severity compared with placebo, as measured by MADRS.

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

The UK-based firm earlier announced that it had met the primary endpoint in the ongoing 258-patient Phase III COMP005 trial, ...

Compass Pathways’ stock has crashed by nearly 50% despite the company announcing its Phase III trial of psilocybin had met ...

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the company’s COMP360 ...

Fintel reports that on June 23, 2025, Evercore ISI Group downgraded their outlook for COMPASS Pathways plc - Depositary ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

American depository receipts of Compass Pathways dropped after trial results for a formulation using the psychedelic psilocybin, designed to help people with treatment-resistant depression, ...